Phreesia (NYSE:PHR) Insider David Linetsky Sells 6,106 Shares

Phreesia, Inc. (NYSE:PHR) insider David Linetsky sold 6,106 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $103,863.06. Following the completion of the sale, the insider directly owned 231,723 shares in the company, valued at $3,941,608.23. This represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Linetsky also recently made the following trade(s):

• On Wednesday, December 17th, David Linetsky sold 94 shares of Phreesia stock. The shares were sold at an average price of $16.49, for a total transaction of $1,550.06.
• On Friday, October 17th, David Linetsky sold 2,059 shares of Phreesia stock. The stock was sold at an average price of $22.36, for a total transaction of $46,039.24.

Phreesia Trading Down 0.6%

Shares of NYSE:PHR opened at $17.14 on Tuesday. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $18.84 and its 200 day moving average price is $23.61. The company has a market cap of $1.03 billion, a PE ratio of -171.33 and a beta of 0.61. Phreesia, Inc. has a fifty-two week low of $15.41 and a fifty-two week high of $32.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.11. The company had revenue of $120.33 million for the quarter, compared to analyst estimates of $119.98 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. Phreesia’s revenue was up 12.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.25) earnings per share. Sell-side analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Institutional Trading of Phreesia

A number of hedge funds and other institutional investors have recently made changes to their positions in PHR. Royal Bank of Canada lifted its stake in Phreesia by 208.8% during the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after purchasing an additional 16,309 shares during the last quarter. AQR Capital Management LLC increased its stake in Phreesia by 471.2% in the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after purchasing an additional 132,015 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Phreesia by 3.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after buying an additional 2,158 shares during the period. NewEdge Advisors LLC lifted its stake in Phreesia by 262.7% during the first quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after buying an additional 11,181 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Phreesia by 0.4% during the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after buying an additional 2,402 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on PHR. Mizuho decreased their price target on Phreesia from $36.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, December 10th. Robert W. Baird reduced their price objective on shares of Phreesia from $31.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phreesia in a research report on Friday, October 31st. Barclays decreased their price objective on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday, December 16th. Finally, JPMorgan Chase & Co. dropped their target price on Phreesia from $32.00 to $29.00 and set an “overweight” rating on the stock in a report on Tuesday, December 9th. Seventeen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.06.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Neutral Sentiment: Royal Bank of Canada initiated coverage on Phreesia. Initiations can increase visibility and trading, but the report does not appear to include a widely circulated bullish or bearish revision that would clearly move consensus. Royal Bank Of Canada Initiates Coverage on Phreesia (NYSE:PHR)
• Negative Sentiment: Citigroup reduced its price target for PHR to $25.00. A lower target from a major broker can weigh on sentiment and reduce upside expectations among investors who follow sell‑side guidance. Citigroup Cuts Phreesia (NYSE:PHR) Price Target to $25.00
• Negative Sentiment: Multiple senior insiders sold shares on Jan. 8 (including the General Counsel, CFO, other officers). Collective insider selling at ~ $17.01 per share (individual Form 4s below) increases float and can be interpreted by some investors as reduced insider conviction, pressuring the stock short‑term. Filings: Allison C. Hoffman (Form 4) SEC Form 4 – Allison C. Hoffman, Balaji Gandhi (CFO) SEC Form 4 – Balaji Gandhi, Evan Roberts SEC Form 4 – Evan Roberts, David Linetsky SEC Form 4 – David Linetsky, Amy Beth Vanduyn SEC Form 4 – Amy Beth Vanduyn, Yvonne Hui SEC Form 4 – Yvonne Hui

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.